New drug IBI129 tested in humans for first time against Hard-to-Treat cancers

NCT ID NCT05991349

Completed Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug might control tumor growth. Because this is a first-in-human study, the results are very preliminary and do not yet show whether IBI129 is an effective treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI129 (an experimental drug given by infusion every 3 weeks)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early, first-in-human study with only 36 participants. The drug may not shrink tumors or may cause side effects. Success in this small trial does not guarantee it will work for larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Chris O'Brien Lifehouse

Camperdown, New South Wales, 2050, Australia
Hubei Cancer Hospital

Wuhan, Hubei, China
Shandong Cancer Hospital

Jinan, Shandong, 250117, China
St George private Hospital

Kogarah, New South Wales, 2217, Australia
The First Hospital of Jilin University

Changchun, Jilin, 130021, China
Tianjin Medical university cancer institute & Hospital

Tianjin, Tianjin Municipality, 300000, China
Wollongong Hospital

Wollongong, New South Wales, 2500, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.